| Q30990540 | "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. |
| Q48207420 | "Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. |
| Q90012537 | 'The same old story': thoughts on authorized doses of anticancer drugs |
| Q34180260 | 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials |
| Q42916333 | A Multicenter Phase-II Study of 5-FU, Leucovorin and Oxaliplatin (FOLFOX6) in Patients with Pretreated Metastatic Colorectal Cancer |
| Q46288489 | A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer |
| Q61628318 | A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer |
| Q42117606 | A long-term survival case of rectal cancer with multiple pulmonary metastases treated with multidisciplinary chemotherapy |
| Q36467960 | A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors |
| Q46742777 | A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer |
| Q34099437 | A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors |
| Q33401396 | A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors |
| Q45228150 | A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer |
| Q37272489 | A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients |
| Q33413523 | A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer |
| Q53518550 | A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study. |
| Q33399530 | A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer |
| Q33931775 | A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. |
| Q34682635 | A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer |
| Q33998072 | A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer |
| Q36778075 | A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). |
| Q36102819 | A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard) |
| Q34344012 | A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer |
| Q36661290 | A review of the role of capecitabine in the treatment of colorectal cancer. |
| Q37468876 | Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. |
| Q43623679 | Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study |
| Q38229589 | Advances and new perspectives in the treatment of metastatic colon cancer |
| Q37867126 | Advances in regional chemotherapy of the liver |
| Q50041173 | An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma |
| Q43954035 | An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. |
| Q34663513 | Analysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile method |
| Q37856782 | Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. |
| Q35783911 | Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival |
| Q26801911 | Anti-angiogenic agents in metastatic colorectal cancer |
| Q24241813 | Anti-angiogenic therapies for metastatic colorectal cancer |
| Q42402968 | Antiangiogenesis therapy in the treatment of metastatic colorectal cancer |
| Q37153292 | Antiangiogenic agents in first-line and second-line therapy for advanced colorectal cancer |
| Q37632167 | Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies |
| Q97522217 | Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients |
| Q41892380 | Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. |
| Q89325917 | Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study |
| Q44136582 | Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. |
| Q35202464 | Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). |
| Q35813229 | Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer |
| Q91819657 | Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial |
| Q30922171 | Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review |
| Q38737493 | Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis |
| Q33424566 | Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial |
| Q38617495 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer |
| Q35767943 | Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study |
| Q41612851 | Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis |
| Q35913223 | Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer |
| Q33403987 | Bevacizumab-induced reversible thrombocytopenia in a patient with adenocarcinoma of colon: rare adverse effect of bevacizumab |
| Q34589084 | Bevacizumab: a review of its use in metastatic colorectal cancer |
| Q38364462 | Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs |
| Q37546065 | Biological mechanisms of bevacizumab-associated adverse events |
| Q86039372 | Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy? |
| Q27010961 | Cancer concepts and principles: primer for the interventional oncologist-part II |
| Q37122339 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients |
| Q35819857 | Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. |
| Q37821286 | Capecitabine for locally advanced and metastatic colorectal cancer: A review |
| Q24633039 | Capecitabine in the management of colorectal cancer |
| Q46965894 | Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. |
| Q37154737 | Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence |
| Q37061596 | Cardiac toxicity: old and new issues in anti-cancer drugs. |
| Q43834221 | Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis |
| Q36757711 | Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma |
| Q58806053 | Chemotherapy re-challenge response rate in metastatic colorectal cancer |
| Q37907117 | Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer |
| Q48526286 | Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer |
| Q33683918 | Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. |
| Q34097734 | Circulating tumor cells in colorectal cancer: past, present, and future challenges |
| Q91638619 | Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis |
| Q38059122 | Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer |
| Q37092129 | Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. |
| Q99605181 | Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments |
| Q47098514 | Comorbid Conditions in Patients With Metastatic Colorectal Cancer |
| Q60309783 | Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis |
| Q57152512 | Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer |
| Q36598736 | Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer |
| Q34410650 | Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study |
| Q43090484 | Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer |
| Q85651019 | Contribution of the β-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity |
| Q34455292 | Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis |
| Q40249789 | Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers |
| Q89929475 | Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer |
| Q35754399 | Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer |
| Q37269696 | Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials |
| Q36286831 | Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer |
| Q37354443 | Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. |
| Q38133409 | Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management |
| Q53259976 | Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials. |
| Q34523039 | Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy |
| Q57758061 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making |
| Q64056579 | Early experience with Watson for oncology in Korean patients with colorectal cancer |
| Q53043230 | Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. |
| Q31060162 | Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature |
| Q26777704 | Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis |
| Q39583831 | Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland |
| Q36828417 | Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study |
| Q35173951 | Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date |
| Q47141058 | Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil |
| Q50594918 | Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. |
| Q36991546 | Evaluation of hypertension as a marker of bevacizumab efficacy |
| Q48870943 | Factors that influence survival in unresectable metastatic or locally advanced colorectal cancer |
| Q35563197 | First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis |
| Q21198874 | First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting |
| Q35705210 | First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study |
| Q33918152 | First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. |
| Q26778990 | Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion |
| Q28211801 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study |
| Q84379489 | Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients |
| Q38528603 | Hepatic Resection for Disappearing Liver Metastasis: a Cost-Utility Analysis. |
| Q37602292 | How to integrate biologicals in the continuum of care |
| Q42007876 | Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer |
| Q37669073 | Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey |
| Q43241630 | Implications of KRAS mutation status for the treatment of metastatic colorectal cancer |
| Q34396212 | Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. |
| Q38005357 | Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers |
| Q38392336 | Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer |
| Q39202110 | Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test |
| Q35172549 | Inhibitory effect of maple syrup on the cell growth and invasion of human colorectal cancer cells |
| Q36396031 | Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings |
| Q36085299 | Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review |
| Q42627821 | Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial |
| Q47574311 | Life and treatment goals of patients with advanced, incurable cancer |
| Q33933669 | Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials |
| Q62581024 | Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study |
| Q38081864 | Management of advanced colorectal cancer, Part 1. |
| Q27026129 | Management of locally advanced and metastatic colon cancer in elderly patients |
| Q38811107 | Management of patients with colorectal liver metastasis in eleven questions and answers |
| Q35076194 | Medical treatment of advanced colorectal cancer in 2009. |
| Q30249335 | Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. |
| Q84444244 | Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy |
| Q36893806 | Metastatic colorectal cancer-past, progress and future |
| Q36920617 | Metastatic colorectal cancer: current systemic treatment options. |
| Q37642801 | Metastatic colorectal cancer: recent advances in its clinical management |
| Q46110280 | Microspheres with ultrahigh holmium content for radioablation of malignancies |
| Q46793061 | Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy |
| Q90399776 | Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature |
| Q46665307 | Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy |
| Q46156144 | Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. |
| Q88001745 | Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer |
| Q36299062 | Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation |
| Q38898002 | Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases. |
| Q34382785 | New approaches in angiogenic targeting for colorectal cancer. |
| Q51817213 | Next generation sequencing of progressive colorectal liver metastases after portal vein embolization. |
| Q49965720 | Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling |
| Q37875058 | Optimal management of metastatic colorectal cancer: current status |
| Q30251387 | Oral drugs in the treatment of metastatic colorectal cancer |
| Q33442681 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis |
| Q24239911 | Oral versus intravenous fluoropyrimidines for colorectal cancer |
| Q38650502 | Oral versus intravenous fluoropyrimidines for colorectal cancer. |
| Q42651373 | Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. |
| Q43413801 | Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases |
| Q39137546 | Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer |
| Q51759783 | Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. |
| Q36169867 | Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience |
| Q38167675 | Palliative treatment of metastatic colorectal cancer: what is the optimal approach? |
| Q37630567 | Pazopanib: an antiangiogenic drug in perspective. |
| Q44488353 | Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia. |
| Q40494253 | Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. |
| Q91260303 | Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study) |
| Q33940893 | Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer |
| Q34165276 | Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer |
| Q33391561 | Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis |
| Q36750569 | Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer |
| Q33624977 | Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing |
| Q40799235 | Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastases. |
| Q36063355 | Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases |
| Q35941562 | Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. |
| Q33841734 | Predicting acute and persistent neuropathy associated with oxaliplatin |
| Q58700971 | Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) - study protocol of a randomized controlled trial with gastrointestinal cancer patients |
| Q38220817 | Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review |
| Q37168808 | Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma |
| Q37780016 | Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. |
| Q92416538 | Pt(IV) Bifunctional Prodrug Containing 2-(2-Propynyl)octanoato Axial Ligand: Induction of Immunogenic Cell Death on Colon Cancer |
| Q48205380 | PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features. |
| Q38826507 | Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. |
| Q34669325 | Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl |
| Q43898732 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. |
| Q90521680 | Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study) |
| Q42292098 | Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer |
| Q37587441 | Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study |
| Q42555130 | Rectal cancer: a review |
| Q38176966 | Regorafenib for treatment of advanced gastrointestinal stromal tumors. |
| Q34343524 | Regorafenib: from bench to bedside in colorectal cancer |
| Q37473177 | Renal toxicity of targeted therapies |
| Q33455278 | Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review |
| Q37560960 | Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q44454368 | Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. |
| Q38103465 | Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. |
| Q33949406 | Risks and benefits with bevacizumab: evidence and clinical implications |
| Q37692395 | Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. |
| Q34335452 | Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer. |
| Q37230238 | Role of oxaliplatin in the treatment of colorectal cancer |
| Q37774980 | Role of surgery in colorectal liver metastases: too early or too late? |
| Q28068817 | Role of targeted therapy in metastatic colorectal cancer |
| Q55318920 | S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT stud |
| Q33403790 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial |
| Q46029883 | Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. |
| Q35076251 | Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. |
| Q37585195 | Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer |
| Q94686663 | Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy |
| Q38216008 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? |
| Q34280051 | Side effects of anti-angiogenic drugs |
| Q41918821 | Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives |
| Q43074534 | Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case |
| Q38137770 | Surgical management of disappearing colorectal liver metastases |
| Q34005111 | Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer |
| Q37158228 | Targeted therapeutic agents for colorectal cancer |
| Q37015697 | Targeted therapies in colorectal cancer: surgical considerations |
| Q30862367 | Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data |
| Q37771243 | Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. |
| Q38216009 | Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives |
| Q33909911 | Targeting metastatic colorectal cancer - present and emerging treatment options |
| Q49056479 | Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise? |
| Q37290510 | The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer |
| Q42353292 | The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice |
| Q27021990 | The development of immunoconjugates for targeted cancer therapy |
| Q36334518 | The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902) |
| Q34773758 | The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials |
| Q37087003 | The management of cancer in the elderly: targeted therapies in oncology |
| Q27011366 | The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer |
| Q35989994 | The risk for anemia with targeted therapies for solid tumors |
| Q38209147 | The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status |
| Q37400010 | The role of targeted therapy in the treatment of advanced colorectal cancer |
| Q38776999 | The safety of monoclonal antibodies for treatment of colorectal cancer |
| Q35908498 | Therapeutic antibodies against cancer |
| Q35419411 | Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab |
| Q37427386 | Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer |
| Q34577462 | Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction |
| Q38531685 | Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review |
| Q36483147 | Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study |
| Q37855303 | Treatment recommendations for metastatic colorectal cancer |
| Q49211979 | Trends in colorectal cancer mortality in hispanics: a SEER analysis |
| Q37815612 | Update on capecitabine alone and in combination regimens in colorectal cancer patients |
| Q37153311 | Update on targeted agents for adjuvant treatment of colon cancer in 2006. |
| Q35076302 | Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity |
| Q26849789 | Value of bevacizumab in treatment of colorectal cancer: A meta-analysis |
| Q64056233 | Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice |
| Q38233043 | XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI. |
| Q33429923 | XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis |
| Q34874473 | Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis |